Helius Medical Technologies Stock EBITDA

HSDT Stock

USD 0.49 0.03 6.52%

Helius Medical Technologies fundamentals help investors to digest information that contributes to Helius Medical's financial success or failures. It also enables traders to predict the movement of Helius Stock. The fundamental analysis module provides a way to measure Helius Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Helius Medical stock.

		Last Reported	Projected for Next Year
	EBITDA	-12.1 M	-12.7 M

EBITDA is likely to drop to about (12.7 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Helius Medical Technologies Company EBITDA Analysis

Helius Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Helius Medical EBITDA

(12.11 M)

Most of Helius Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Helius Medical Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Helius EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Helius Medical is extremely important. It helps to project a fair market value of Helius Stock properly, considering its historical fundamentals such as EBITDA. Since Helius Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Helius Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Helius Medical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Net Receivables	Short Term Investments	Capital Surpluse	Deferred Long Term Liab	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Good Will	Intangible Assets
Total Assets		0.74	0.7	-0.98	-0.68	0.35	0.77	0.71	0.99	0.53	-0.18	0.45	0.42	-0.09	0.69	0.45	0.11	0.86	0.84	0.51	-0.14	-0.34	-0.33
Total Stockholder Equity	0.74		0.89	-0.69	-0.62	-0.23	0.14	0.45	0.71	0.17	-0.7	0.24	0.03	-0.04	0.74	0.24	0.02	0.91	0.86	0.56	-0.3	-0.39	-0.37
Net Tangible Assets	0.7	0.89		-0.62	-0.79	-0.32	0.19	0.6	0.68	0.09	-0.7	0.55	0.2	-0.47	0.89	0.55	-0.28	0.87	0.9	0.56	-0.57	-0.69	-0.7
Net Debt	-0.98	-0.69	-0.62		0.55	-0.36	-0.79	-0.59	-0.99	-0.62	0.14	-0.35	-0.31	-0.01	-0.56	-0.35	-0.13	-0.77	-0.76	-0.35	0.04	0.25	0.24
Retained Earnings	-0.68	-0.62	-0.79	0.55		-0.01	-0.41	-0.92	-0.64	0.13	0.27	-0.81	-0.64	0.52	-0.96	-0.81	0.4	-0.85	-0.9	-0.63	0.66	0.83	0.8
Accounts Payable	0.35	-0.23	-0.32	-0.36	-0.01		0.73	0.36	0.35	0.52	0.8	0.2	0.57	0.25	-0.13	0.2	0.41	0.01	-0.08	0.05	0.29	0.35	0.33
Total Liab	0.77	0.14	0.19	-0.79	-0.41	0.73		0.63	0.8	0.62	0.39	0.43	0.58	-0.09	0.31	0.43	0.14	0.4	0.42	0.22	0.08	-0.14	-0.14
Short Long Term Debt	0.71	0.45	0.6	-0.59	-0.92	0.36	0.63		0.68	0.07	0.04	0.8	0.78	-0.44	0.85	0.8	-0.19	0.76	0.77	0.63	-0.54	-0.63	-0.61
Total Current Assets	0.99	0.71	0.68	-0.99	-0.64	0.35	0.8	0.68		0.57	-0.15	0.44	0.39	-0.1	0.64	0.44	0.07	0.81	0.81	0.42	-0.11	-0.34	-0.34
Short Term Debt	0.53	0.17	0.09	-0.62	0.13	0.52	0.62	0.07	0.57		0.15	-0.01	-0.05	0.2	-0.07	-0.01	0.51	0.14	0.06	-0.04	0.3	0.34	0.32
Common Stock	-0.18	-0.7	-0.7	0.14	0.27	0.8	0.39	0.04	-0.15	0.15		0.03	0.37	0.2	-0.48	0.03	0.07	-0.48	-0.47	-0.38	0.29	0.34	0.32
Long Term Debt	0.45	0.24	0.55	-0.35	-0.81	0.2	0.43	0.8	0.44	-0.01	0.03		0.8	-0.6	0.72	1.0	-0.39	0.5	0.57	0.45	-0.62	-0.7	-0.73
Net Receivables	0.42	0.03	0.2	-0.31	-0.64	0.57	0.58	0.78	0.39	-0.05	0.37	0.8		-0.33	0.49	0.8	-0.12	0.37	0.39	0.52	-0.24	-0.39	-0.41
Short Term Investments	-0.09	-0.04	-0.47	-0.01	0.52	0.25	-0.09	-0.44	-0.1	0.2	0.2	-0.6	-0.33		-0.52	-0.6	0.56	-0.17	-0.3	-0.26	0.63	0.7	0.77
Capital Surpluse	0.69	0.74	0.89	-0.56	-0.96	-0.13	0.31	0.85	0.64	-0.07	-0.48	0.72	0.49	-0.52		0.72	-0.27	0.9	0.92	0.72	-0.67	-0.77	-0.74
Deferred Long Term Liab	0.45	0.24	0.55	-0.35	-0.81	0.2	0.43	0.8	0.44	-0.01	0.03	1.0	0.8	-0.6	0.72		-0.39	0.5	0.57	0.45	-0.62	-0.7	-0.73
Current Deferred Revenue	0.11	0.02	-0.28	-0.13	0.4	0.41	0.14	-0.19	0.07	0.51	0.07	-0.39	-0.12	0.56	-0.27	-0.39		-0.04	-0.27	0.25	0.49	0.8	0.82
Net Invested Capital	0.86	0.91	0.87	-0.77	-0.85	0.01	0.4	0.76	0.81	0.14	-0.48	0.5	0.37	-0.17	0.9	0.5	-0.04		0.96	0.69	-0.43	-0.53	-0.5
Net Working Capital	0.84	0.86	0.9	-0.76	-0.9	-0.08	0.42	0.77	0.81	0.06	-0.47	0.57	0.39	-0.3	0.92	0.57	-0.27	0.96		0.61	-0.44	-0.71	-0.68
Property Plant Equipment	0.51	0.56	0.56	-0.35	-0.63	0.05	0.22	0.63	0.42	-0.04	-0.38	0.45	0.52	-0.26	0.72	0.45	0.25	0.69	0.61		-0.17	-0.29	-0.28
Capital Stock	-0.14	-0.3	-0.57	0.04	0.66	0.29	0.08	-0.54	-0.11	0.3	0.29	-0.62	-0.24	0.63	-0.67	-0.62	0.49	-0.43	-0.44	-0.17		0.66	0.65
Good Will	-0.34	-0.39	-0.69	0.25	0.83	0.35	-0.14	-0.63	-0.34	0.34	0.34	-0.7	-0.39	0.7	-0.77	-0.7	0.8	-0.53	-0.71	-0.29	0.66		0.97
Intangible Assets	-0.33	-0.37	-0.7	0.24	0.8	0.33	-0.14	-0.61	-0.34	0.32	0.32	-0.73	-0.41	0.77	-0.74	-0.73	0.82	-0.5	-0.68	-0.28	0.65	0.97

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Helius Medical

Ebitda Over Time

Helius Ebitda

Ebitda

(12.71 Million)

At this time, Helius Medical's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Helius Medical Technologies reported earnings before interest,tax, depreciation and amortization of (12.11 Million). This is 101.38% lower than that of the Health Care Equipment & Supplies sector and 101.88% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.31% higher than that of the company.

Helius EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Helius Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Helius Medical could also be used in its relative valuation, which is a method of valuing Helius Medical by comparing valuation metrics of similar companies.

Helius Medical is currently under evaluation in ebitda category among its peers.

Helius Medical Institutional Holders

Institutional Holdings refers to the ownership stake in Helius Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Helius Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Helius Medical's value.

		Shares
St Germain D J Co Inc	2024-09-30	2.0
Wells Fargo & Co	2024-06-30	0.0
Armistice Capital, Llc	2024-09-30	0.0
Geode Capital Management, Llc	2024-09-30	17.8 K
Susquehanna International Group, Llp	2024-06-30	16.3 K
Vanguard Group Inc	2024-09-30	12.6 K
Tower Research Capital Llc	2024-06-30	6.9 K
Ubs Group Ag	2024-06-30	1.5 K
Corecap Advisors, Llc	2024-06-30	200
Advisor Group Holdings, Inc.	2024-06-30	80.0
Federation Des Caisses Desjardins Du Quebec	2024-06-30	37.0

Helius Fundamentals

	Return On Equity	-1.62
	Return On Asset	-0.76
	Operating Margin	(17.97) %
	Current Valuation	(1.73 M)
	Shares Outstanding	3.73 M
	Shares Owned By Insiders	0.52 %
	Shares Owned By Institutions	5.80 %
	Number Of Shares Shorted	225.38 K
	Price To Earning	(13.85) X
	Price To Book	0.45 X
	Price To Sales	2.89 X
	Revenue	644 K
	Gross Profit	324 K
	EBITDA	(12.11 M)
	Net Income	(8.85 M)
	Cash And Equivalents	3.27 M
	Cash Per Share	0.12 X
	Total Debt	57 K
	Debt To Equity	0.03 %
	Current Ratio	2.85 X
	Book Value Per Share	3.29 X
	Cash Flow From Operations	(10.42 M)
	Short Ratio	0.34 X
	Earnings Per Share	(4.27) X
	Target Price	4.0
	Number Of Employees	22
	Beta	1.61
	Market Capitalization	1.72 M
	Total Asset	7.69 M
	Retained Earnings	(159.96 M)
	Working Capital	5.56 M
	Current Asset	6.8 M
	Current Liabilities	4.46 M
	Net Asset	7.69 M

About Helius Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Helius Medical Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helius Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helius Medical Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Helius Stock Analysis

When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC